Navigation Links
ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
Date:2/14/2011

CHICAGO, Feb. 14, 2011 /PRNewswire/ -- Zoledronic acid (sold by Novartis as Zometa, Aclasta, and Reclast) is used to treat Osteoporosis, Tumor Metastasis, and Paget's Disease with sales of $2 billion a year.(1)  It is associated with side effects such as post-dose syndrome and osteonecrosis of the jaw.  A new patented method from Dr. Ketan Desai enables the administration of Zoledronic acid in combination with another drug that relieves the side effects.

(Logo:  http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

This patented method will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City. Key Characteristics of MethodThe patents disclose the following:


  • Method enables administration of zoledronic acid in a novel combination.
  • Method results in decreased side effects.
  • Can be administered though different methods: oral supply, inhalation, muscle injection, or veindrip.
  • Market OverviewThese patents may be of interest in the following areas:


  • The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expect to reach $32.8 billion in 2013.(2)
  • These patents would be of interest to: pharmaceutical companies, drug manufacturers, healthcare service providers, and biomedical research.
  • To learn more about the assets available for sale in this portfolio: Contact Dean Becker of ICAP Ocean Tomo at Dean.Becker@us.icap.comAbout ICAP Ocean Tomo LLCICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.

    About ICAPICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.

    (1) http://www.thepharmaletter.com/file/100554/novartis-zometa-fails-to-meet-ph-iii-primary-endpoint-in-early-breast-cancer-stalling-this-indication-but-afinitor-looks-good.html

    (2) http://www.bccresearch.com/report/HLC026C.html


    '/>"/>

    SOURCE ICAP Ocean Tomo
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
    2. ICAP Ocean Tomo to Auction 7 Exclusive Licenses from Lawrence Livermore National Laboratory at Fall Auction November 11th in Napa, California
    3. Skin Lesion Identification System to Auction on November 11th at ICAP Ocean Tomos Fall 2010 Live IP Auction
    4. ICAP Ocean Tomo Offers for Sale IP Portfolio of Active Implants for Electromagnetic Bone and Tissue Regeneration in Orthopedics, Trauma, and Wound Care
    5. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
    6. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
    7. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
    8. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
    9. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
    10. Dynatronics Announces Fiscal Second Quarter Results
    11. K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/22/2017)... 22, 2017 TapImmune, Inc. ... the development of innovative peptide and gene-based immunotherapeutics ... today announced that it will participate in two ... Glynn Wilson , Chairman and CEO of ... business, clinical pipeline and partnering opportunities for its ...
    (Date:3/22/2017)... -- Piramal Pharma Solutions (PPS), a leading ... event to introduce the new and expanded manufacturing capabilities ... . The inaugural event was attended by Governor ... and Piramal Pharma Solutions CEO, Vivek Sharma . ... ...
    (Date:3/22/2017)... March 22, 2017 A new independent ... is the proven ultraviolet-C (UV-C) disinfection solution of ... (HAIs). Published in the March ... Control , the peer-reviewed study of UV-C disinfection ... Vancouver General Hospital and Rochester General Hospital. According ...
    Breaking Medicine Technology:
    (Date:3/22/2017)... ... March 22, 2017 , ... Influence Health, the ... solutions have enabled Children’s Hospital of The King’s Daughters (CHKD) to achieve a ... value of a digital marketing approach, the 206-bed pediatric teaching hospital in Norfolk, ...
    (Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... An intensive ... could occasionally transmit HIV, reports Leslie Norins, MD, PhD. He says investigating ... of domestically transmitted Zika virus and in new infections with HIV. , ...
    (Date:3/22/2017)... Providence, RI (PRWEB) , ... March 22, 2017 ... ... Dr. Gwynne Bragdon to its Department of Orthopedic Surgery, Division of Hand, Upper ... extremity and orthopedic surgery. She is board-certified in both Orthopedics and Hand ...
    (Date:3/22/2017)... ... March 22, 2017 , ... Last year, 43 million gallons ... Department of Agriculture report. While excess dairy can be caused by several factors, ... sensitivity is the inability to properly digest lactose, a sugar found in milk and ...
    (Date:3/22/2017)... ... March 22, 2017 , ... The Carballo ... Jersey and the New York metropolitan region, is embarking on a cooperative charity ... families. , At present, more than two and a half million children in ...
    Breaking Medicine News(10 mins):